Literature DB >> 24075740

Long-term use of statins reduces the risk of hospitalization for dementia.

Giovanni Corrao1, Buthaina Ibrahim, Federica Nicotra, Antonella Zambon, Luca Merlino, Thea Scognamiglio Pasini, Alberico L Catapano, Giuseppe Mancia.   

Abstract

BACKGROUND: Dementia is a major public health problem because of its high prevalence in elderly individuals, particularly in the growing category of subjects aged 80 years or more. There is accumulating evidence that cholesterol may be implicated in the pathogenesis of dementia, and this has led us to assess the relationship between time spent with statins available and the risk of hospitalization for dementia.
METHODS: A population-based, nested case-control study was carried out by including the cohort of 152,729 patients from Lombardy (Italy) aged 40 years or older who were newly treated with statins between 2003 and 2004. Cases were the 1380 patients who experienced hospitalization for dementia disease from initial prescription until 2010. Up to twenty controls were randomly selected for each case. Logistic regression was used to model the risk of dementia associated with the cumulative time during which statins were available. Monte-Carlo and rule-out sensitivity analyses were performed to account for unmeasured confounders.
RESULTS: Compared with patients who had very short statins coverage (less than 6 months), those on 7-24, 25-48, and >48 months of coverage respectively had risk reductions of 15% (OR: 0.85; 95% CI: 0.74 to 0.98), 28% (OR: 0.72; 95% CI: 0.61 to 0.85), and 25% (OR: 0.75; 95% CI: 0.61 to 0.94). Simvastatin and atorvastatin were both associated with a reduced risk of dementia, while no similar evidence was observed for fluvastatin and pravastatin.
CONCLUSIONS: Long-term use of statins seems effective for the prevention of dementia.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia; Healthcare Utilization Database; Lipid-lowering agents; Monte-Carlo sensitivity analysis; Record linkage; Rule-out sensitivity analysis; Statins; Unmeasured confounders

Mesh:

Substances:

Year:  2013        PMID: 24075740     DOI: 10.1016/j.atherosclerosis.2013.07.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

Review 1.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

Review 2.  Antiaging Therapies, Cognitive Impairment, and Dementia.

Authors:  Devin Wahl; Rozalyn M Anderson; David G Le Couteur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

Review 3.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

Review 4.  Promoting Successful Cognitive Aging: A Ten-Year Update.

Authors:  Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 5.  Probabilistic bias analysis in pharmacoepidemiology and comparative effectiveness research: a systematic review.

Authors:  Jacob N Hunnicutt; Christine M Ulbricht; Stavroula A Chrysanthopoulou; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-09-05       Impact factor: 2.890

Review 6.  Antilipidemic Drug Therapy Today and in the Future.

Authors:  Werner Kramer
Journal:  Handb Exp Pharmacol       Date:  2016

7.  Long-term mortality in obese subjects undergoing malabsorptive surgery (biliopancreatic diversion and biliointestinal bypass) versus medical treatment.

Authors:  Valerio Ceriani; Giuliano Sarro; Giancarlo Micheletto; Alessandro Giovanelli; Ahmed S Zakaria; Marco Fanchini; Chiara Osio; Italo Nosari; Alberto Morabito; Antonio E Pontiroli
Journal:  Int J Obes (Lond)       Date:  2018-11-23       Impact factor: 5.095

8.  Long-term mortality and incidence of cardiovascular diseases and type 2 diabetes in diabetic and nondiabetic obese patients undergoing gastric banding: a controlled study.

Authors:  Antonio E Pontiroli; Ahmed S Zakaria; Ermanno Mantegazza; Alberto Morabito; Alessandro Saibene; Enrico Mozzi; Giancarlo Micheletto
Journal:  Cardiovasc Diabetol       Date:  2016-02-27       Impact factor: 9.951

9.  Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors.

Authors:  Satyajeet Roy; Joshua Louis Weinstock; Allyse Sachiko Ishino; Jefferson Felix Benites; Samantha Rachel Pop; Christopher David Perez; Edvard Adrian Gumbs; Jennifer Ann Rosenbaum; Mary Kate Roccato; Hely Shah; Gabriela Contino; Krystal Hunter
Journal:  J Clin Med Res       Date:  2017-05-22

Review 10.  Neuroprotective effects of statins against amyloid β-induced neurotoxicity.

Authors:  Hsin-Hua Li; Chih-Li Lin; Chien-Ning Huang
Journal:  Neural Regen Res       Date:  2018-02       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.